Medical therapies for meningiomas
| Autor: | Patrick Y. Wen, Rameen Beroukhim, Jan Drappatz, Andrew D. Norden, Eudocia C. Quant |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Population Brain tumor Antineoplastic Agents Radiosurgery chemistry.chemical_compound Epidermal growth factor Internal medicine medicine Meningeal Neoplasms Humans education Chemotherapy education.field_of_study business.industry medicine.disease Vascular endothelial growth factor Clinical trial Radiation therapy Neurology chemistry Immunology Hormonal therapy Neurology (clinical) Cranial Irradiation business Meningioma |
| Zdroj: | Journal of neuro-oncology. 99(3) |
| ISSN: | 1573-7373 |
| Popis: | Meningiomas are the most common primary brain tumor in adults. Although the majority of these tumors can be effectively treated with surgery and radiation therapy, an important subset of patients have inoperable tumors, or develop recurrent disease after surgery and radiotherapy, and require some form of medical therapy. There are increasing numbers of studies evaluating various medical therapies but the results remain disappointing. Chemotherapies and hormonal therapies have been generally ineffective, although somatostatin analogues may have therapeutic potential. There is also increasing interest in targeted molecular therapies. Agents inhibiting platelet derived growth factor receptors and epidermal growth factor receptors have shown little efficacy, but molecular agents inhibiting vascular endothelial growth factor receptors appear to have some promise. As with other tumors, advances in the medical therapies for meningiomas will require improved understanding of the molecular pathogenesis of these tumors, more predictive preclinical models, and efficient mechanisms for conducting clinical trials, given the small population of eligible patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink